Results 81 to 90 of about 104,914 (293)

A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011 [PDF]

open access: yes, 2013
Background and objective: The Global initiative for chronic Obstructive Lung Disease(GOLD) Committee has proposed a chronic obstructive pulmonary disease (COPD) assessment framework focused on symptoms and on exacerbation risk. This study will evaluate a
Betsuyaku, T   +7 more
core   +1 more source

When Biology Meets Medicine: A Perspective on Foundation Models

open access: yesAdvanced Intelligent Discovery, EarlyView.
Artificial intelligence, and foundation models in particular, are transforming life sciences and medicine. This perspective reviews biological and medical foundation models across scales, highlighting key challenges in data availability, model evaluation, and architectural design.
Kunying Niu   +3 more
wiley   +1 more source

Small vesicles, big potential: A review of innovative exosome delivery and molecular mechanisms in preclinical myocardial infarction models

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This narrative review discusses animal models of exosome‐based myocardial infarction treatments. Emerging techniques aim to improve exosome stability, targeting, and bioavailability for MI treatment as drug delivery vehicles and regenerative mediators that promote myocardial regeneration. Abstract Exosomes have emerged as promising therapeutic carriers,
Chayanisa Phutiyothin   +2 more
wiley   +1 more source

Novel cruzain inhibitors for the treatment of Chagas' disease. [PDF]

open access: yes, 2012
The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas' disease, affects millions of individuals and continues to be an important global health concern.
Arkin, Michelle R   +6 more
core   +1 more source

Opioid Drug Death Investigations [PDF]

open access: yesAcademic Forensic Pathology, 2017
Opioid-related deaths have transitioned over the past 15 years, beginning with a steady increase in the incidence of fatal prescription overdoses, followed by a dramatic increase in deaths caused by illicit opioids, namely heroin and fentanyl. These trends in drug-related deaths are identified by medical examiners and coroners who serve an important ...
openaire   +2 more sources

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence

open access: yesJournal of Experimental Pharmacology, 2020
Juilia Sellarès-Nadal, Joaquin Burgos, Vicenç Falcó, Benito Almirante Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona, Barcelona, SpainCorrespondence: Benito ...
Sellarès-Nadal J   +3 more
doaj  

Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial [PDF]

open access: yes, 2014
David R Coghill,1 Tobias Banaschewski,2 Michel Lecendreux,3 César Soutullo,4 Alessandro Zuddas,5 Ben Adeyi,6 Shaw Sorooshian7 1Division of Neuroscience, University of Dundee, Dundee, UK; 2Child and Adolescent Psychiatry and Psychotherapy, Central
Alessandro Alessandro Zuddas   +7 more
core   +6 more sources

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy